Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

Stress causes whole body deterioration

Stress, to put it bluntly, is bad for you. It can kill you, in fact. A study now reveals that stress causes deterioration in everything from your gums to your heart and can make you more susceptible to everything from the common cold to cancer.

9 Jan 2008

Brain response differences found in way women with irritable bowel syndrome deal with pain

UCLA researchers found that women with IBS cannot effectively turn-off a pain modulation mechanism in the brain, which causes them to be more sensitive to abdominal pain, compared to women without IBS.

9 Jan 2008

Why do mental illness and drug addiction so often go together?

New research reveals that this type of dual diagnosis may stem from a common cause: developmental changes in the amygdala, a walnut-shaped part of the brain linked to fear, anxiety and other emotions.

3 Dec 2007

FDA warns about 'stay awake drug' Provigil

The U.S. Food and Drug Administration (FDA) has issued a warning in connection with the drug Provigil because of dangerous side effects.

28 Oct 2007

Sanofi Pasteur receives FDA approval of Menactra meningococcal vaccine for children

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include children 2 years through 10 years of age.

22 Oct 2007

Prebiotics in infants for prevention of allergic disease and food hypersensitivity

Many parents add prebiotics and probiotics to children's food to help treat health problems, and according to two new reviews, the supplements might also help prevent eczema in babies at high risk.

17 Oct 2007

New analyses of long-term LIALDA (mesalamine) data presented at ACG

Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.

16 Oct 2007

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).

18 Sep 2007

No link between short term cell phone use and brain cancer

Cell phones have not been found to be associated with any biological or adverse health effects, according to the UK's largest investigation into the possible health risks from cell telephone technology.

13 Sep 2007

DES: friend or foe?

The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.

3 Sep 2007

Cannabis for allergic contact dermatitis

Administering a substance found in the cannabis plant can help the body's natural protective system alleviate an allergic skin disease (allergic contact dermatitis), an international group of researchers from Germany, Israel, Italy, Switzerland and the U.S. has found.

17 Aug 2007

Sanofi pasteur ships doses of Fluzone influenza vaccine for the 2007-2008 season

Sanofi pasteur, the vaccines division of the sanofi-aventis Group, has begun shipment of influenza vaccine (Fluzone, Influenza Virus Vaccine) in the United States for the 2007-2008 season.

13 Aug 2007

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

Sucampo Pharmaceuticals, Inc., has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).

13 Jul 2007

Baxter presents findings from the ADAPT study

Baxter Healthcare Corporation has announced the presentation of findings from the ADAPT (Analysis of Data from ADVATE Prospective Trials) study program database showing a statistically significant relationship between the duration of time spent with factor VIII blood levels below one international unit per deciliter (1 IU/dL, one percent of normal factor VIII level) and an increase in the annual bleed rate in people with hemophilia A.

11 Jul 2007

Early diagnosis and prevention of the effects of tooth erosion are fundamental to keeping teeth healthy for life

Fruit, yogurt, citric and soft drinks, may seem like harmless snacks and beverages, but improper consumption and overuse may lead to devastating and permanent damage to teeth. It's known as tooth erosion, the break down of tooth structure caused by the effect of acid on the teeth that leads to decay.

26 Jun 2007

Greater understanding of fibromyalgia as a true medical condition

Fibromyalgia, a chronic, widespread pain in muscles and soft tissues accompanied by fatigue, is a fairly common condition that does not manifest any structural damage in an organ.

26 Jun 2007

Novel method of drug delivery to inhibit the growth of prostate cancer cells

Prostate cancer is the second leading cause of cancer-related death for men in the U.S. Present treatments for metastatic prostate cancer (cancer cells that spread to other parts of the body) include hormonal therapy, chemotherapy and radiotherapy, which frequently have serious side effects.

23 Jun 2007

Genzyme files for FDA approval of single-treatment Synvisc-One

Genzyme Corp. has announced that it has filed with the U.S. Food and Drug Administration (FDA) for approval of Synvisc-One, the single treatment of Synvisc (hylan G-F 20) that provides up to six months of pain relief from osteoarthritis (OA) of the knee.

23 Jun 2007

FDA approves Norditropin for short stature in children with Noonan syndrome

Novo Nordisk has announced that Norditropin (somatropin[rDNA origin] injection) received U.S. Food and Drug Administration (FDA) approval for the treatment of short stature in children with Noonan syndrome.

3 Jun 2007

Diagnosis of aspirin hypersensitivity

A position paper on the diagnosis of aspirin hypersensitivity by a team of European scientists from the Global Allergy and Asthma European Network (GA2LEN) has just been published on the Allergy Journal website.

1 Jun 2007